A First-In-Kind Universal Influenza Vaccine Could Make This Small Biotech A Strong Buy

“Imagine the market for an influenza vaccine that would not require modifications each year to address annual mutations in the influenza virus, that brings about immunity to strains of the influenza virus that do not even exist at the time of inoculation, and maintains immunity for at least four years,” requests the author of today’s article before proceeding to highlight a small biotech company with such a universal influenza vaccine candidate in the final stages of development – one which is very likely to successfully complete its pivotal Phase 3 trial by the end of October and be approved for market. For more on this small, undervalued biotech and its first-in-kind influenza vaccine, CLICK HERE.